Cancer BiologyFrontiers in OncologyPeer-reviewed
Potent Estrogen Receptor β Agonists with Inhibitory Activity In Vitro, Fail to Suppress Xenografts of Endocrine-Resistant Cyclin-dependent Kinase 4/6 inhibitor-Resistant Breast Cancer Cells
Lynn M. Marcho, Christopher Charles Coss, Menglin Xu…·Mathew Amprayil Cherian
The paper tests the in vivo efficacy of estrogen receptor β agonists combined with tamoxifen in endocrine-resistant breast cancer models, finding no tumor volume reduction despite in vitro success.
2 citations